Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selonsertib for compensated NASH cirrhosis
NL-OMON45452Phase 3Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of selonsertib in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis (3 arms), sponsored by Gilead Sciences. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
selonsertib
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on NL-OMON45452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45452.